Literature DB >> 15772185

Atrial fibrillation: will new drugs and patient choice improve anticoagulation outcomes?

R Fuller, N J Dudley.   

Abstract

The growing epidemic of atrial fibrillation presents major challenges to the healthcare community, both clinical and financial.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15772185      PMCID： PMC1768851          DOI： 10.1136/hrt.2004.047902

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


  17 in total

1.  Warfarin in atrial fibrillation: underused in the elderly, often inappropriately used in the young.

Authors:  R G Hart
Journal:  Heart       Date:  1999-11       Impact factor: 5.994

2.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.

Authors:  B F Gage; A D Waterman; W Shannon; M Boechler; M W Rich; M J Radford
Journal:  JAMA       Date:  2001-06-13       Impact factor: 56.272

3.  Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population.

Authors:  M Jones; P McEwan; C Ll Morgan; J R Peters; J Goodfellow; C J Currie
Journal:  Heart       Date:  2005-04       Impact factor: 5.994

4.  Physician attitudes concerning warfarin for stroke prevention in atrial fibrillation: results of a survey of long-term care practitioners.

Authors:  J Monette; J H Gurwitz; P A Rochon; J Avorn
Journal:  J Am Geriatr Soc       Date:  1997-09       Impact factor: 5.562

5.  Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups.

Authors:  J W Gorter
Journal:  Neurology       Date:  1999-10-12       Impact factor: 9.910

6.  Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison.

Authors:  M E Cromheecke; M Levi; L P Colly; B J de Mol; M H Prins; B A Hutten; R Mak; K C Keyzers; H R Büller
Journal:  Lancet       Date:  2000-07-08       Impact factor: 79.321

7.  Evaluation of computerized decision support for oral anticoagulation management based in primary care.

Authors:  D A Fitzmaurice; F D Hobbs; E T Murray; C P Bradley; R Holder
Journal:  Br J Gen Pract       Date:  1996-09       Impact factor: 5.386

8.  Avoidance hierarchies and preferences for anticoagulation--semi-qualitative analysis of older patients' views about stroke prevention and the use of warfarin.

Authors:  Richard Fuller; Nigel Dudley; Jon Blacktop
Journal:  Age Ageing       Date:  2004-09-22       Impact factor: 10.668

9.  Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial.

Authors:  Hans-Christoph Diener; Julien Bogousslavsky; Lawrence M Brass; Claudio Cimminiello; Laszlo Csiba; Markku Kaste; Didier Leys; Jordi Matias-Guiu; Hans-Jürgen Rupprecht
Journal:  Lancet       Date:  2004 Jul 24-30       Impact factor: 79.321

10.  Prevalence of atrial fibrillation and eligibility for anticoagulants in the community.

Authors:  M Sudlow; R Thomson; B Thwaites; H Rodgers; R A Kenny
Journal:  Lancet       Date:  1998-10-10       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.